

Special Issue

New Advances in Neurodevelopmental Disorders: From Genetics to Mechanisms

Message from the Guest Editors

Neurodevelopmental disorders (NDDs) have proven to be genetically and phenotypically heterogeneous. Many groups have published novel NDD candidate genes from large cohorts, but the lack of understanding of the pathomechanisms for these genetic variants has created a clinical bottleneck. Currently, we have a significantly stronger understanding of the genetics of NDDs compared with molecular mechanisms. Furthermore, we need further information on the clinical phenotypes of individuals with these novel genetic variants to better characterize individual NDDs. With a better understanding of both the molecular mechanisms and phenotypic spectra, targeted therapeutics may become more available. Addressing the gaps between genomics and the clinic is critical for patient care. This Special Issue of *Biomedicines* will focus on the data necessary for understanding the full picture of NDDs. This includes primary research and/or review articles focused on molecular or animal studies modeling specific disorders, deep genotype-phenotype analyses, and novel ways to understand the genetics of NDDs.

Guest Editors

Dr. Madelyn A. Gillentine

Molecular Laboratory, Seattle Children's Hospital, Seattle, WA, USA

Dr. Jennifer M. Bain

Division of Child Neurology, Department of Neurology, Columbia University Irving Medical Center, New York, NY, USA

Deadline for manuscript submissions

closed (30 June 2023)



Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed



mdpi.com/si/120962

Biomedicines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
biomedicines@mdpi.com

[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)





Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed



[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)



About the Journal

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 14.6 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the second half of 2024).